Progress and challenges in RET-targeted cancer therapy.
10.1007/s11684-023-0985-y
- Author:
Xueqing HU
1
;
Ujjwol KHATRI
1
;
Tao SHEN
1
;
Jie WU
2
Author Information
1. Peggy and Charles Stephenson Cancer Center, and Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
2. Peggy and Charles Stephenson Cancer Center, and Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. jie-wu@oushc.edu.
- Publication Type:Review
- Keywords:
RET-alteration;
drug resistance;
lung cancer;
pralsetinib;
selpercatinib;
thyroid cancer;
tumor-agnostic therapy
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/genetics*;
Neoplasm, Residual;
Lung Neoplasms/genetics*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*;
Proto-Oncogene Proteins c-ret/genetics*
- From:
Frontiers of Medicine
2023;17(2):207-219
- CountryChina
- Language:English
-
Abstract:
The rearranged during transfection (RET) is a receptor protein tyrosine kinase. Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer, but also increasingly in various types of cancers at low rates. In the last few years, two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and received regulatory approval. Although pralsetinib and selpercatinib gave high overall response rates (ORRs), < 10% of patients achieved a complete response (CR). The RET TKI-tolerated residual tumors inevitably develop resistance by secondary target mutations, acquired alternative oncogenes, or MET amplification. RET G810 mutations located at the kinase solvent front site were identified as the major on-target mechanism of acquired resistance to both selpercatinib and pralsetinib. Several next-generation of RET TKIs capable of inhibiting the selpercatinib/pralsetinib-resistant RET mutants have progressed to clinical trials. However, it is likely that new TKI-adapted RET mutations will emerge to cause resistance to these next-generation of RET TKIs. Solving the problem requires a better understanding of the multiple mechanisms that support the RET TKI-tolerated persisters to identify a converging point of vulnerability to devise an effective co-treatment to eliminate the residual tumors.
